MATERNUS-Kliniken AG (DE:MAK)

XETRA:MAK

MAK

MATERNUS-Kliniken AG

RESEARCH TOOLSreports

Want to see DE:MAK full AI Analyst Report?

MATERNUS-Kliniken AG (MAK) Price & Analysis

2 Followers

MAK Stock Chart & Stats

€0.98

-€0.01(-0.71%)

At close: Jan 08 4:00 PM EST

€0.98

-€0.01(-0.71%)

Day’s Range― - ―

52-Week Range€0.89 - €10.90

Previous CloseN/A

Volume132.00

Average Volume (3M)618.00

Market Cap

€18.98M

Enterprise Value€19.00M

Total Cash (Recent Filing)€2.18M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta0.58

Next Earnings

Aug 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.72

Shares Outstanding20,970,000

10 Day Avg. Volume1,293

30 Day Avg. Volume618

Financial Highlights & Ratios

PEG Ratio-0.32

Price to Book (P/B)-0.27

Price to Sales (P/S)0.18

P/FCF Ratio1.92

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Stable Cash GenerationConsistent positive operating and free cash flow in 2024–2025 provides a durable liquidity buffer that supports ongoing operations, maintenance capex and working capital needs. Over 2–6 months this cash generation reduces immediate refinancing pressure and enables incremental deleveraging or targeted reinvestment.

Recurring Revenue ModelA core business of long-term residential and nursing care creates recurring, contract-like revenue streams that are more predictable than transactional businesses. This structural revenue base tends to smooth cash flows, supports occupancy-driven margins, and provides a stable foundation for multi-month operational planning and cost management.

Improving Operating TrendNarrowing losses and an improving operating trend across 2024–2025 indicate progress on cost control or operational efficiency. If sustained, this structural improvement can translate into steady margin recovery and greater resilience to revenue variability across the next several months, aiding medium-term viability.

Bears Say

Negative Shareholders' EquityMaterial negative equity reflects cumulative losses and an impaired capital base that limits financing options. Structurally this elevates refinancing and covenant risk, narrows strategic flexibility for capex or acquisitions, and makes the company more dependent on external capital solutions over the medium term.

High Leverage Vs AssetsDebt materially exceeding reported assets creates a structurally fragile balance sheet that constrains flexibility. High nominal leverage increases refinancing needs, raises interest burden sensitivity, and limits the company's ability to absorb revenue shocks or invest in service improvements without external support.

Sharp 2025 Revenue DeclineA one‑year ~33% revenue contraction is a structural red flag for demand or portfolio stability. Such a steep drop undermines operating leverage, pressures margins and cash conversion, and makes sustained profitability harder to achieve absent clear drivers of recovery or structural remediation.

MAK FAQ

What was MATERNUS-Kliniken AG’s price range in the past 12 months?

MATERNUS-Kliniken AG lowest stock price was €0.89 and its highest was €10.90 in the past 12 months.

What is MATERNUS-Kliniken AG’s market cap?

MATERNUS-Kliniken AG’s market cap is €18.98M.

When is MATERNUS-Kliniken AG’s upcoming earnings report date?

MATERNUS-Kliniken AG’s upcoming earnings report date is Aug 20, 2026 which is in 70 days.

How were MATERNUS-Kliniken AG’s earnings last quarter?

MATERNUS-Kliniken AG released its earnings results on Apr 30, 2026. The company reported -€0.563 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.563.

Is MATERNUS-Kliniken AG overvalued?

According to Wall Street analysts MATERNUS-Kliniken AG’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does MATERNUS-Kliniken AG pay dividends?

MATERNUS-Kliniken AG does not currently pay dividends.

What is MATERNUS-Kliniken AG’s EPS estimate?

MATERNUS-Kliniken AG’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does MATERNUS-Kliniken AG have?

MATERNUS-Kliniken AG has 20,970,000 shares outstanding.

What happened to MATERNUS-Kliniken AG’s price movement after its last earnings report?

MATERNUS-Kliniken AG reported an EPS of -€0.563 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8%.

Which hedge fund is a major shareholder of MATERNUS-Kliniken AG?

Currently, no hedge funds are holding shares in DE:MAK

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

MATERNUS-Kliniken AG Stock Smart Score

Underperform

Technicals

Top Smart Score Stocks >

Company Description

MATERNUS-Kliniken AG

Maternus-Kliniken AG oversees a network of facilities that includes retirement and nursing residences, rehabilitation centers, and a variety of specialized service companies. This enterprise primarily focuses on delivering geriatric care and medical rehabilitation services. Furthermore, it offers an extensive range of support options, such as emergency response systems, assisted living arrangements, and various care modalities including home care, residential care, temporary stays, and care for individuals with disabilities. Its services also encompass comprehensive rehabilitation and post-treatment programs. The company maintains roughly 23 establishments throughout Germany. Founded in 1877, Maternus-Kliniken AG's corporate headquarters are situated in Berlin, Germany.